再鼎医药(09688.HK)完成美国包销发售ADR 每股150美元
再鼎医药(09688.HK)公布,已向美国证交会提交8-K表格,完成於美国包销发售477.6万股美国预托股份(ADR),每股ADR代表1股普通股,价格为每股ADR 150美元。公司已授予ADR发售包销商30日选择权,以按发售价额外购买最多71.64万股ADR。包销商已悉数行使彼等之选择权以购买该等额外ADR。相关ADR发售已於上周五(23日)完成。
公司预期全球发售所得款项总额合共约为8.58亿美元,公司来自ADR发售之所得款项总额约8.24亿美元。普通股发售预期将於周三(28日)或前後完成,将以港元结算,价格为每股普通股1,164.2元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.